Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
Prefunded Warrants
Series B - warrant liability
Common Stock
Common Stock
Prefunded Warrants
Common Stock
Series B - warrant liability
Additional Paid-In Capital
Additional Paid-In Capital
Prefunded Warrants
Additional Paid-In Capital
Series B - warrant liability
Accumulated Deficit
Balance (in shares) at Dec. 31, 2020       288,074,415            
Balance at Dec. 31, 2020 $ 450,786     $ 288,074     $ 38,896,693     $ (38,733,981)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense (in shares)       1,350,000            
Stock-based compensation expense 856,206     $ 1,350     854,856      
Issuance of common stock and warrants, net of issuance costs (in shares)       58,111,112            
Issuance of common stock and warrants, net of issuance costs of $935,260 6,062,774     $ 58,111     6,004,663      
Warrant exercises (in shares)   11,800,000     11,800,000 116,666,668        
Warrant exercises   $ 11,800 $ 6,999,999   $ 11,800 $ 116,666     $ 6,883,333  
Exercise of stock options (in shares)       106,250            
Exercise of stock options 4,783     $ 107     4,676      
Net loss for the year ended (8,522,182)                 (8,522,182)
Balance (in shares) at Dec. 31, 2021       476,108,445            
Balance at Dec. 31, 2021 5,864,166     $ 476,108     52,644,221     (47,256,163)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense (in shares)       1,483,332            
Stock-based compensation expense 629,032     $ 1,483     627,549      
Warrant exercises (in shares)   19,666,667     19,666,667          
Warrant exercises   $ 1,967     $ 19,667     $ (17,700)    
Exercise of stock options 4,000,000                  
Common stock, options and warrants issued for asset acquisition, net of issuance costs (in shares)       416,270,514            
Common stock, options and warrants issued for asset acquisition, net of issuance costs of $25,511 9,858,155     $ 416,270     9,441,885      
Finance charge from Sciences warrant modification 120,228           120,228      
Net loss for the year ended (19,481,602)                 (19,481,602)
Balance (in shares) at Dec. 31, 2022       913,528,958            
Balance at Dec. 31, 2022 $ (3,008,054)     $ 913,528     $ 62,816,183     $ (66,737,765)